Showing 1 - 4 results of 4 for search 'Jean A Hurteau', query time: 0.02s
Refine Results
-
1
Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study by Dana M. Chase, Soham Shukla, Julia Moore, Tirza Areli Calderón Boyle, Jonathan Lim, Jessica Perhanidis, Jean A. Hurteau, Jeanne M. Schilder
Published 2024-08-01
Article -
2
Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study by Bobbie Rimel, Tirza Areli Calderón Boyle, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M. Schilder, Jean A. Hurteau, Amanda Golembesky
Published 2024-07-01
Article -
3
Niraparib as First-Line Maintenance Therapy in Patients with Stage III Ovarian Cancer and No Visible Residual Disease: AR1ZE Real-World Study by Dana M. Chase, Maya Hanna, Jonathan T. Lim, Tirza Areli Calderón Boyle, Mark Guinter, Madeline Richey, Khilna Patel, Jeanne M. Schilder, Jean A. Hurteau, Amanda K. Golembesky
Published 2025-01-01
Article -
4
Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphos... by Bobbie J. Rimel, Dana M. Chase, Jessica Perhanidis, Armen A. Ghazarian, Ella Xiaoyan Du, Travis Wang, Jinlin Song, Amanda K. Golembesky, Jean A. Hurteau, Linda Kalilani, Ritu Salani, Bradley J. Monk
Published 2024-02-01
Article